HepNet patient registry- secondary prevention of hepatic encephalopathy

HepNet patient registry- secondary prevention of hepatic encephalopathy - HE-Register

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009691

Enrollment

250

Registered

2015-11-23

Start date

2014-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Encephalopathy K72.9

Interventions

Group 1: Patients after hospitalization with documented clinically-manifest HE Documentation of standard diagnostics Implementation of PSE Syndrome Test Measurement of flicker frequencies Questionnai

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients (> 18 years) with symptomatic hepatic encephalopathy, which required hospitalization in the last 3 months

Exclusion criteria

Exclusion criteria: hospitalization at baseline. max. 50 patients will be enrolled with MELD> 20 (Should this have a strong negative impact on the recruitment, the number can be increased).

Design outcomes

Primary

Measure	Time frame
Period until the re-hospitalization because of acute episodes of clinically manifest hepatic encephalopathy	—

Secondary

Measure	Time frame
Frequencies of the decline of the baseline Westhaven criteria 2. Change in West Haven criteria with respect to baseline 3. Changes in PSE Syndrome Test compared to baseline 4. Changes of the flicker frequency compared to baseline 5. Detection of important influencing factors on disease progression (genetic analysis, Demographics) 6. Comparison of disease progression between the forms of therapy (administration vs. non-delivery of a drug) 7. Application of relevant concomitant medications, time of first dose, duration, dose	—

Measure

Time frame

Frequencies of the decline of the baseline Westhaven criteria 2. Change in West Haven criteria with respect to baseline 3. Changes in PSE Syndrome Test compared to baseline 4. Changes of the flicker frequency compared to baseline 5. Detection of important influencing factors on disease progression (genetic analysis, Demographics) 6. Comparison of disease progression between the forms of therapy (administration vs. non-delivery of a drug) 7. Application of relevant concomitant medications, time of first dose, duration, dose

—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026